Raymond James analyst Martin Auster initiated coverage of Edgewise Therapeutics (EWTX) with a Strong Buy rating and $46 price target The firm sees a highly attractive risk/reward profile for the shares at current levels. Edgewise’s Phase 2 CIRRUS-HCM Part D results in the second half of 2025 can “meaningfully de-risk” EDG-7500 in hypertrophic cardiomyopathy, the analyst tells investors in a research note. The firm sees a path forward for the drug to potentially avoid a risk evaluation and mitigation strategy.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EWTX:
- Edgewise Therapeutics initiated with a Buy at H.C. Wainwright
- Edgewise Therapeutics price target lowered to $35 from $40 at Wedbush
- Edgewise Therapeutics Announces Positive Sevasemten Results
- Morning Movers: Shell ticks higher after denying interest in BP deal
- Edgewise update in line with expectations, says Leerink